Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia Post author: Post published:March 1, 2026 Post category: Continue ReadingAutologous Muscle Derived Cells for Treatment of Tongue Dysphagia
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy Post author: Post published:March 1, 2026 Post category: Continue ReadingRESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Treatment of Moderate to Severe Refractory Crohn’s Disease Post author: Post published:March 1, 2026 Post category: Continue ReadingTreatment of Moderate to Severe Refractory Crohn’s Disease
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Post author: Post published:March 1, 2026 Post category: Continue ReadingA Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells Post author: Post published:March 1, 2026 Post category: Continue ReadingAnti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Post author: Post published:March 1, 2026 Post category: Continue ReadingAnti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
